2019
A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.
Powell M, Filiaci V, Hensley M, Huang H, Moore K, Tewari K, Copeland L, Secord A, Mutch D, Santin A, Richards W, Warshal D, Spirtos N, Disilverstro P, Ioffe O, Miller D. A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial. Journal Of Clinical Oncology 2019, 37: 5500-5500. DOI: 10.1200/jco.2019.37.15_suppl.5500.Peer-Reviewed Original ResearchQuality of lifeOverall survivalEligible ptsRandomized phase 3 trialSimilar QOLStratified log-rank testAggressive epithelial malignancyNew standard regimenNRG Oncology trialsStages I-IVbChemotherapy-naive patientsPhase 3 trialLog-rank testPhase 2 activityGenitourinary hemorrhageNeurotoxicity scoresO cohortRecurrent carcinosarcomaPrimary endpointStandard regimenLonger PFSHazard ratioOptimal therapyGynecologic carcinosarcomaEpithelial malignancies
2013
Updates in therapy for uterine serous carcinoma
Roque DM, Santin AD. Updates in therapy for uterine serous carcinoma. Current Opinion In Obstetrics & Gynecology 2013, 25: 29-37. PMID: 23138439, DOI: 10.1097/gco.0b013e32835af98d.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaSerous carcinomaTreatment of USCPaclitaxel-resistant diseasePI3/Akt/mTOR pathwayClass III β-tubulinEarly-stage diseaseNew target antigensAKT/mTOR pathwayVascular endothelial growth factorDistinct molecular pathogenesisHER2/neuIII β-tubulinCurrent clinical approachesEndothelial growth factorNovel microtubule-stabilizing agentEndometrial cancerAggressive variantOptimal therapyProspective studyPathway aberrationsClinical investigationSmall molecule inhibitorsTarget antigenClinical approach